Abstract-Dietary intake of various fats may have different effects on blood pressure. We conducted a prospective cohort study to examine the association between intake of subtype and individual fatty acids (FAs) and the risk of developing hypertension among 28 100 US women aged Ն39 years and free of cardiovascular disease and cancer. Baseline intake of FAs was assessed using semiquantitative food frequency questionnaires. Incident hypertension was identified from annual follow-up questionnaires based on self-reported physician diagnosis, medication use, and blood pressure levels. A total of 13 633 women developed incident hypertension during 12.9 years of follow-up. After adjusting for demographic, lifestyle, and other dietary factors, intake of saturated FAs, monounsaturated FAs, and trans-unsaturated FAs (trans FAs) was positively associated with the risk of hypertension. The multivariable relative risks and 95% CIs of hypertension in the highest compared with the lowest quintile of intake were 1.12 (1.05 to 1.20) for saturated FAs, 1.11 (1.04 to 1.18) for monounsaturated FAs, and 1.15 (1.08 to 1.22) for trans FAs. After additional adjustment for body mass index and history of diabetes mellitus and hypercholesterolemia, these associations were attenuated and remained statistically significant only for trans FAs (relative risk in the highest quintile: 1.08; 95% CI: 1.01 to 1.15). Intake of polyunsaturated FAs, including 3 and 6 polyunsaturated FAs, was not significantly associated with the risk of hypertension. In conclusion, higher intake of saturated FAs, monounsaturated FAs, and trans FAs was each associated with increased risk of hypertension among middle-aged and older women, whereas only association for trans FAs remained statistically significant after adjustment for obesity-related factors. (Hypertension. 2010;56:00-00.)
D
ietary fat is an important modifiable risk factor for hypertension. 1 Interventions that reduce total fat intake can effectively lower systolic and diastolic blood pressures (BPs). [2] [3] [4] Recent research further suggests that subtypes of fat with different molecular structure may have different effects on BP. 5, 6 Investigations using animal models have shown that diets high in saturated fats increase BP, 7, 8 whereas diets enriched with 3 polyunsaturated fats protect against induced BP elevations. 9 -11 In previous epidemiological studies, BP has been shown positively correlated with saturated fats intake 12, 13 and inversely correlated with monounsaturated 13 and polyunsaturated fats intake. 14, 15 Only a few studies have examined the prospective association between dietary fat intake 16, 17 or its biomarkers in blood 18, 19 and the risk of developing hypertension, with inconsistent results reported. In randomized trials, reduction of saturated fats intake alone did not seem to affect BP 20 ; increase of polyunsaturated (particularly 3) fats intake can lower BP, whereas the effect was primarily found among hypertensive but not normotensive individuals. [21] [22] [23] To better understand the different roles of various dietary fats in the development of hypertension, we conducted a prospective analysis in a large cohort of middle-aged and older US women to investigate the association between baseline intake of saturated fatty acids (FAs; SFAs), monounsaturated FAs (MUFAs), polyunsaturated FAs (PUFAs), and trans-unsaturated FAs (trans FAs) and the subsequent risk of hypertension during long-term follow-up.
Methods

Study Population
The Women's Health Study (WHS) is a randomized, double-blind, placebo-controlled, 2ϫ2 factorial trial evaluating the risks and benefits of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer. 24, 25 A third component, ␤-carotene, was initially included in the trial but terminated after a median treatment of 2.1 years. 26 Written informed consent was obtained from all of the participants. The trial and ongoing cohort follow-up were approved by the institutional review board of Brigham and Women's Hospital (please see http://hyper.ahajournals. org). From September 1992 to May 1995, 39 876 female US health professionals, aged Ն39 years and free from cardiovascular disease and cancer (except nonmelanoma skin cancer), were randomized into the WHS. Of the 39 876 women randomized, 39 310 completed a 131-item validated semiquantitative food frequency questionnaire (FFQ) . For this study, we excluded 10 751 women who had hypertension at baseline, defined as having a self-reported physician diagnosis of hypertension, self-reported current systolic BP Ն140 mm Hg or diastolic BP Ն90 mm Hg, or use of antihypertensive treatment. We also excluded 829 women who reported implausible total daily energy intake, 21 women who provided incomplete information on the FFQ, and 41 women who had prerandomization cardiovascular disease or cancer. After these exclusions, a baseline population of 28 100 women remained for analysis.
Assessment of Dietary Fat Intake
On the baseline FFQ, a commonly used unit or portion size was specified for each food item. Participants were asked how often they had consumed that amount, on average, during the previous year. Nine possible responses ranging from "never or less than once per month" to "6ϩ per day" were recorded. Nutrient intake was computed by multiplying the intake frequency of each unit of food by the nutrient content of the specified portion size according to food composition tables from the US Department of Agriculture, 27 supplemented with information obtained from the manufacturers and published reports. The estimation of fat intake also took into account the types of fat or oil used during food preparation. The trans isomer contents of unsaturated fats were estimated based on the method proposed by Sacks and Willett. 28 Intakes of SFAs, MUFAs, PUFAs, and trans FAs were each calculated as sum of the respective individual FAs. All of the FA intakes presented in the current study have adjusted for total energy intake using the residual method. 29 In similar cohorts of health professionals, Pearson correlation coefficients comparing responses from the FFQ with those from four 1-week dietary records spaced over a year were 0.70 for SFAs, 0.69 for MUFAs, and 0.64 for PUFAs. 30, 31 FA intakes estimated from the FFQ also correlated well with FA composition of the adipose tissue (Spearman rϭ0.51 for trans FAs and 0.48 for 3 PUFAs). 32 
Ascertainment of Incident Hypertension
Incident hypertension was ascertained from annual follow-up questionnaires by meeting Ն1 of 4 criteria: (1) a new physician diagnosis of hypertension; (2) newly initiated antihypertensive treatment; (3) self-reported current systolic BP Ն140 mm Hg; or (4) self-reported current diastolic BP Ն90 mm Hg. Women reported the month and year of hypertension diagnosis. For incident cases missing dates of physician diagnosis or defined by other criteria, time of event was assigned by randomly selecting a date between the questionnaires with and without hypertension. Individuals who developed cardiovascular disease during follow-up, the management of which may affect BP, were censored on the date of cardiovascular disease diagnosis. In health professionals, self-reported BP correlates well with measured systolic BP (rϭ0.72) and diastolic BP (rϭ0.60), 33 and the validity of self-reported hypertension is high. 34 In a random sample of WHS participants, self-reported incident hypertension was confirmed in 48 (96%) of 50 women and absence of hypertension was confirmed in 45 (90%) of 50 women through telephone interviews.
Data Analyses
Statistical analyses were performed using SAS software (SAS Institute) version 9.1. Intake of FAs was divided into quintiles. Distribution of hypertension risk factors was compared across quintiles of FAs intake. Person-years of follow-up were calculated for each participant from randomization to the date of incident hypertension, the last day in the study, or February 29, 2007 , whichever came first. After verifying the assumption of constant proportional hazard, we used Cox regression model to estimate the hazard ratio (presented as relative risk [RR] ) and 95% CI of hypertension across quintiles of FAs intake, with the lowest quintile as the reference. Models first adjusted for age, race, total energy intake, and randomized treatment assignment and then additionally adjusted for lifestyle factors, including smoking, total alcohol intake, physical activity, postmenopausal status, postmenopausal hormone use, and several hypertension-related nutritional factors, including dietary intake of calcium, potassium, sodium, and fiber (multivariable model 1), and finally adjusted for obesity-related metabolic factors that may also serve as intermediate factors linking dietary FAs to hypertension development, including body mass index (BMI), history of diabetes mellitus, and history of hypercholesterolemia (multivariable model 2). Analyses were further stratified by known hypertension risk factors including age (Ͻ55 or Ն55 years), BMI (Ͻ25 or Ն25 kg/m 2 ), smoking status (current or noncurrent), alcohol intake (none or any), and physical activity (Ͻ600 or Ն600 kcal/week). We also performed several sensitivity analyses. First, we repeated all of the analyses with dietary FAs represented as the percentage of total energy intake; second, we considered incident hypertension using alternative definitions, such as self-reported elevated BP only, physician diagnosis or antihypertensive treatment only, or multiple indications. The results of sensitivity analyses were similar to main analyses (data not shown).
Results
Among 28 100 women free of hypertension at baseline, energy-adjusted FA intake ranged from 2.55 to 51.4 g/d for SFAs, 3.39 to 52.0 g/d for MUFAs, 2.10 to 40.5 g/d for PUFAs, and 0.01 to 12.4 g/d for trans FAs. SFA and MUFA intakes were highly correlated (Pearson rϭ0.78). PUFA intake was moderately correlated with MUFA intake (rϭ0.55) and weakly but significantly correlated with SFA intake (rϭ0.26). Trans FAs intake was moderately correlated with SFA (rϭ0.52) and MUFA (rϭ0.63) intake and weakly correlated with PUFA intake (rϭ0.31). Table 1 shows the baseline characteristics of participants by quintiles of SFA, MUFA, and PUFA intake. For all 3 of the FA subtypes, women consuming greater amounts were heavier, more likely to be current smokers, less physically active, and had lower alcohol intake. Women consuming more SFAs and MUFAs were younger, less likely to be postmenopausal and use postmenopausal hormones, and less likely to have hypercholesterolemia, whereas they were more likely to be diabetic. Intake of all 3 of the FA subtypes was also positively associated with intake of sodium and inversely associated with intake of calcium, potassium, and fiber. Baseline systolic and diastolic BPs increased with increasing intake of all 3 of the FA subtypes. The associations of hypertension risk factors with trans FA intake were similar to the associations with SFA and MUFA intake (data not shown).
A total of 13 633 cases of incident hypertension were identified during an average of 12.9 years of follow-up, with 2427 cases identified by elevated systolic or diastolic BP only, 61 cases identified by physician diagnosis only, 1540 cases identified by newly initiated antihypertensive medications only, and the remaining cases identified by multiple indications. After adjusting for age, race, total energy intake, and randomized treatment, the risk of hypertension significantly increased across increasing intake of all of the FA subtypes except 3 PUFAs. Additional adjustment for lifestyle factors and nutritional factors (multivariable model 1) attenuated these associations. Intake of SFAs, MUFAs, and trans FAs remained significantly and positively associated with risk of hypertension, whereas intake of PUFAs was only marginally significantly associated with risk of hypertension (Table 2) . After further adjustment for BMI, diabetes mellitus, and hypercholesterolemia (multivariable model 2), the associations for SFA, MUFA, and PUFA intake were all attenuated to null; only the positive association for trans FAs intake remained significant, with the fully adjusted RRs of hypertension across increasing quintiles of 1.00, 1.04, 1.07, 1.06, and 1.08 (P for trendϭ0.04). There was an inverse association of polyunsaturated:saturated FA ratio and a positive association of 6:3 PUFAs ratio with risk of hypertension in the reduced model (data not shown), but these associations were no longer significant in the multivariable models (Table 2) .
We further stratified the analyses by baseline age (Figure) . The positive associations of SFA, MUFA, and trans FA intakes with risk of hypertension all appeared to be stronger for women aged Ͻ55 years than for older women, albeit the test for age-related interactions reached statistical significance only for trans FAs. The multivariable model 2 RRs of hypertension across increasing quintiles of trans FA intake among women aged 39 to Ͻ55 years were 1.00, 1.11, 1.12, 1.14, and 1.21 (P for trendϽ0.0001). The corresponding RRs among women aged 55 to 89 years were 1.00, 0.95, 1.01, 0.96, and 0.91 (P for trendϭ0.09). The associations between dietary FAs and hypertension risk only slightly varied by baseline BMI, smoking status, alcohol consumption, and physical activity (all Ps for interaction: Ͼ0.05).
The associations of major individual FA intake with risk of hypertension largely followed the associations for their respective FA subtypes (Table S1, 
Discussion
In this large-scale prospective cohort study of middle-aged and older women, intake of SFAs, MUFAs, and trans FAs was each positively associated with risk of hypertension. The associations for SFAs and MUFAs were largely attenuated by 7 and enhanced sympathetic nervous system activities, 8 which will increase BP. In contrast, consumption of long-chain 3 PUFAs modulated plasma phospholipid composition and cell membrane fluidity, increased the production of vasodilators, and reduced cardiac adrenergic activity, 5,35 which will lower BP. The incorporation of 6 PUFAs into cell membrane changed *Linear trends across increasing quintiles of FAs intake were tested using the median value of each quintile as an ordinal variable. †Multivariable model 1 was adjusted for age (continuous), race (white or nonwhite), total energy intake (continuous), treatment (vitamin E, aspirin, ␤-carotene, or placebo), smoking (never, former, or current), alcohol intake (continuous), physical activity (continuous), postmenopausal status (yes, no, or uncertain), postmenopausal hormone use (never, former, or current), dietary sodium, potassium, calcium, and fiber (all in quintiles). ‡Multivariable model 2 was adjusted for all of the covariates in multivariable model 1 plus BMI (continuous), history of diabetes mellitus (yes or no), and history of hypercholesterolemia (yes or no).
the balance between vasoconstrictors and vasodilators, 5 and the subsequent net effects on BP have varied in different animal models. 36, 37 Similarly, MUFAs also modify membrane phospholipid composition 38 and vascular reactivity, 39 the net effects of which may either raise or lower BP. Direct effects of trans FAs on BP remain largely unclear. Because of the lack of flexible structure of their parent unsaturated FAs, trans FAs display biological features more similar to SFAs. 40 Furthermore, because trans FAs compete with other unsaturated FAs for enzymatic desaturation, the presence of trans FAs may increase the demand for essential PUFAs. 41 Previous prospective studies linking FA intake with incident hypertension have yielded inconsistent results. In the Nurses' Health Study, 16 a cohort of 121 700 US women aged 34 to 59 years, and the Health Professionals Follow-Up Study, 17 a cohort of 51 529 US men aged 40 to 75 years, no association was found between baseline intake of SFAs, MUFAs, PUFAs, or trans FAs assessed from FFQ and incident hypertension during a short follow-up of 4 years. Two studies investigated the association between plasma FAs, as biomarker for dietary FAs, and risk of hypertension. 18, 19 The Atherosclerosis Risk in Communities Study found that higher levels of SFAs and MUFAs and lower levels of PUFAs and polyunsaturated:saturated FA ratio in baseline plasma phospholipids and cholesterol ester were significantly associated with an increased 6-year incidence of hypertension. 18 The Uppsala Longitudinal Study of Adult Men showed that the baseline plasma levels of SFA 16:0 and 
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18:0 were significantly higher and the plasma level of PUFA 18:26 was significantly lower in men who developed sustained hypertension compared with men who remained normotensive or had white-coat hypertension. 19 Both studies did not examine trans FAs in plasma. In randomized trials, dietary interventions that lowered saturated fat intake alone did not significantly affect BP 20 ; diets rich in MUFAs reduced BP levels 42 or antihypertensive medication required for hypertensive patients in some 43 but not all 20 studies; 3 PUFA supplementation lowered BP in hypertensive individuals but not in normotensives, and the substantial BP reductions usually occurred at relatively high doses (Ն3 g/d) [21] [22] [23] ; and 6 PUFA (mainly 18:26) supplements have not demonstrated apparent effects on BP. 20 We are not aware of any clinical trial that tested the effect of reducing dietary trans fats on BP or risk of developing hypertension. In our study, the positive associations of SFA, MUFA, and trans FA intakes with risk of hypertension were substantially attenuated after adjustment for BMI. This finding underscored a potential confounding effect of obesity in the dietary fat and hypertension relation. Alternatively, because dietary fat is a major source of energy that may contribute to the development of obesity, a strong impact of BMI in the FA-hypertension relation also possibly reflects that obesity and its related pathophysiological processes are important intermediate steps linking fat intake to BP change. Another intriguing finding in our study is that the associations between subtype and individual FA intake with risk of hypertension have appeared stronger among younger women versus older women. However, the test for age-related interactions only reached statistical significance for trans FAs. The lack of a clear association between intake of 3 PUFA, 6 PUFA, and 6:3 ratio with risk of hypertension, although consistent with findings from previous studies that measured plasma FAs as biomarker for dietary FAs, 18, 19 was unexpected. Although in vivo and in vitro experimental studies demonstrated potential effects of PUFAs on BP control, the amount of PUFA intake in our study population is probably insufficient to strongly affect the risk of developing hypertension among initially normotensive individuals. Another possible explanation for the lack of association for PUFAs is residual confounding by unknown factors that correlate with high PUFA intake or supplement use.
Strengths of the current study include the prospective study design, large sample size, and minimal loss to follow-up. However, several limitations of this study also deserve comment. First, the assessment of dietary FA intake and ascertainment of incident hypertension are based on selfreported information in our study. Nevertheless, the validity and reproducibility of FFQ as a measure of long-term dietary intake 30 -32 and the accuracy of self-reported hypertension in health professionals 33, 34 have been demonstrated in previous validation studies. For lifestyle and clinical covariates, including BMI, a single baseline assessment is subject to misclassification considering possible change during followup, whereas random misclassification will typically lead to an underestimation of true association. Second, because correlations among intake of SFAs, MUFAs, and trans FAs were moderate to high in our study, we cannot completely separate their effects from each other. Third, despite comprehensive adjustment for multiple lifestyle and clinical factors, residual confounding by unmeasured or imprecisely measured hypertension risk factors may persist. Fourth, although our large sample size allowed us to assess the association between dietary FAs and risk of hypertension in various subgroups, the potential for false-positive findings implies that we should interpret any significant findings in subgroup analysis with caution. Finally, WHS participants are predominantly white female health professionals, which minimized potential confounding by race/ethnicity and socioeconomic factors but also may limit study generalizability. Yet similar associations noted in previous community-based studies 18, 19 suggest that our results may indeed be generalizable to other populations.
Perspectives
Current dietary guidelines for US adults recommend total fat intake between 20% and 35% of calories, saturated FAs intake Ͻ10% of calories, and trans FA consumption as low as possible. 44 Epidemiological evidence on the relevance of such dietary recommendations to the prevention of hypertension is surprisingly limited. With total fat intake as a percentage of calories falling over recent decades, 45 more specific recommendations on the optimal amount and type of FA intake for hypertension and cardiovascular disease prevention are needed. Our study comprehensively examined the association between intake of subtype and individual FAs and risk of hypertension. Our findings support the importance of current dietary fat recommendations for middle-aged and older women. Our findings also suggest that an adverse diet profile, along with other unhealthy lifestyle, may increase the risk of hypertension through promoting obesity. More studies are warranted to further elucidate the interrelation among dietary fat, the development of obesity, and the pathogenesis of hypertension. Table S1 . Multivariable relative risks and 95% confidence intervals of hypertension in the highest quintile compared to the lowest quintile of individual fatty acid intake, stratified by baseline age.
Individual fatty acids
Aged * Linear trends across increasing quintiles of FAs intake were tested using the median value of each quintile as an ordinal variable. † Short-to medium-chain saturated fatty acids, including 4:0 (butyric acid), 6:0 (caproic acid), 8:0 (caprylic acid), 10:0 (capric acid), and 12:0 (lauric acid), were combined due to the low percentage in total fat intake and similar food sources.
